A Phase-I Clinical Study to Evaluate the Safety, Pharmacokinetics and Anti-Tumor Activity of NRC-AN-019 in Patients with Solid Tumors.

ATCO Pharma Ltd0 sites0 target enrollmentTBD

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

November 1, 2010

Last Updated

3 years ago

Study Type

Interventional

Sponsor

ATCO Pharma Ltd

•1\. Patients must be greater than or equal 18 years old with expected life expectancy greater than 8 weeks.
•2\. Patients with disease not responding to currently available treatment options.
•3\. Patients must have recovered from the toxic effects of earlier radiotherapy or chemotherapy (if any)
•4\. Patients must have adequate bone marrow reserve
•5\. Patients must be willing to practice birth control during and for two months after treatment with study drug
•6\. Patients who are willing and able to give informed consent
•7\. Patients should have ECOG performance status less than or equal to 2\.

•1\. Patients with major illness including active cardiac, hepatic, endocrine, renal or psychiatric disorders inadequately controlled with current therapy.
•2\. Concurrent use of other chemotherapeutic agents
•3\. Pregnancy or lactation or non\-practice of birth control during and for 2 months after treatment with study drug
•4\. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study, and which may obscure the evaluation of toxicity or alters drug metabolism.